drugset / Trial / NCT02619617

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617

Phase 2 Terminated 28 enrolled Novartis Pharmaceuticals
Non-randomizedSequentialDouble-blindTreatment

Summary

The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.

Timeline

Start
2016-10-31
Primary completion
2018-09-25
Completion
2018-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Pasireotide Other / unclassified 0.9 mg Subcutaneous
Subject Pasireotide Other / unclassified 1.5 mg Subcutaneous